Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Aethlon Medical (AEMD) EBITDA Margin (2016 - 2023)

Aethlon Medical (AEMD) has disclosed EBITDA Margin for 13 consecutive years, with 431.51% as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, EBITDA Margin rose 2843170.0% year-over-year to 431.51%, compared with a TTM value of 2199.15% through Dec 2023, up 9850607.0%, and an annual FY2025 reading of 287.57%, changed N/A over the prior year.
  • EBITDA Margin was 431.51% for Q1 2023 at Aethlon Medical, up from 28863.21% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 211.97% in Q4 2019 and bottomed at 28863.21% in Q1 2022.
  • Average EBITDA Margin over 5 years is 5679.0%, with a median of 1590.14% recorded in 2021.
  • The sharpest move saw EBITDA Margin tumbled -2224590bps in 2022, then soared 2843170bps in 2023.
  • Year by year, EBITDA Margin stood at 211.97% in 2019, then crashed by -85bps to 391.18% in 2020, then crashed by -3675bps to 14768.63% in 2021, then tumbled by -95bps to 28863.21% in 2022, then soared by 99bps to 431.51% in 2023.
  • Business Quant data shows EBITDA Margin for AEMD at 431.51% in Q1 2023, 28863.21% in Q1 2022, and 14768.63% in Q4 2021.